THE STUDY by Zito and colleagues1 in this issue of the ARCHIVES is a welcome first step in understanding the clinical use of stimulant medications in the treatment of attention-deficit/hyperactivity disorder (ADHD). The controversy about treatment with methylphenidate hydrochloride raised in the popular press2,3 continues despite the fact that ADHD and its treatment with stimulant medications and psychosocial interventions have been rigorously studied to a greater degree than any other mental disorder.4,5 The continued concern is the perception that too many children are being treated with stimulant medication.6 The evidence to date suggests that, while there may be inappropriate treatment with methylphenidate as implied by the wide variation in physician and local prescription rates,7 the variations include both undertreatment and overtreatment such that the prevalence of stimulant medication use does not exceed the most commonly accepted prevalence rates for the disorder.8,9 The study by Zito et al further substantiates these findings in that while they found a considerable increase in the number of children treated, the treatment prevalence within the practices was still within the most frequently cited prevalence range.8,9 It is actually similar to prevalence rates in a group of Iowa pediatricians and family practitioners from 1987.10
Mark L. Wolraich, MD
Thank you for submitting a comment on this article. It will be reviewed by JAMA Pediatrics editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 5
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.